Aberrant regulation of FBW7 in cancer

Lixia Wang; Xiantao Ye; Yueyong Liu; Wenyi Wei; Zhiwei Wang

doi:10.18632/oncotarget.1859

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

Aberrant regulation of FBW7 in cancer

Lixia Wang, Xiantao Ye, Yueyong Liu, Wenyi Wei _ and Zhiwei Wang

PDF | HTML | How to cite

Oncotarget. 2014; 5:2000-2015. https://doi.org/10.18632/oncotarget.1859

Metrics: PDF 4319 views | HTML 6401 views | ?

Abstract

Lixia Wang1,*, Xiantao Ye1,*, Yueyong Liu2, Wenyi Wei2, Zhiwei Wang1,

1 The Cyrus Tang Hematology Center, Jiangsu Institute of Hematology, the First Affiliated Hospital, Soochow University, Suzhou, China

2 Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, MA, USA

* These authors contributed equally to this work

Correspondence:

Wenyi Wei, email:

Zhiwei Wang, email:

Keywords:cancer, tumor suppressor, FBW7, SCF, ubiquitination, oncoprotein

Received: March 13, 2014 Accepted: March 24, 2014 Published: March 25, 2014

Abstract

FBW7 (F-box and WD repeat domain-containing 7) or Fbxw7 is a tumor suppressor, which promotes the ubiquitination and subsequent degradation of numerous oncoproteins including Mcl-1, Cyclin E, Notch, c- Jun, and c-Myc. In turn, FBW7 is regulated by multiple upstream factors including p53, C/EBP-δ, EBP2, Pin1, Hes-5 and Numb4 as well as by microRNAs such as miR-223, miR-27a, miR-25, and miR-129-5p. Given that the Fbw7 tumor suppressor is frequently inactivated or deleted in various human cancers, targeting FBW7 regulators is a promising anti-cancer therapeutic strategy.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 1859

Publication Alerts

Reviews:

Aberrant regulation of FBW7 in cancer

Abstract